Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins☆ | Zendy

Thomas Schachner | Zendy; Christina Steger | Zendy; Simone Heiss | Zendy; Nikolaos Bonaros | Zendy; William Sterlacci | Zendy; Günther Laufer | Zendy; Johannes Bonatti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins☆

Author(s) -

Thomas Schachner,

Christina Steger,

Simone Heiss,

Nikolaos Bonaros,

William Sterlacci,

Günther Laufer,

Johannes Bonatti

Publication year - 2007

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2007.09.015

Subject(s) - neointimal hyperplasia , paclitaxel , saphenous veins , hyperplasia , cardiology , medicine , restenosis , vein , chemotherapy , stent

Paclitaxel exerts antiproliferative properties by stabilizing microtubuli of the cell. The substance is in clinical use for drug-eluting coronary stents. We aimed to test the hypothesis that paclitaxel treatment can reduce neointimal hyperplasia in cultured human saphenous veins and thus might be useful for local pharmacologic treatment of vein grafts prior to coronary artery bypass grafting (CABG).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research